Literature DB >> 28007970

Dual effects of fructose on ChREBP and FoxO1/3α are responsible for AldoB up-regulation and vascular remodelling.

Wei Cao1,2, Tuanjie Chang3, Xiao-Qiang Li4, Rui Wang5,6,7, Lingyun Wu8,6,9.   

Abstract

Increased production of methylglyoxal (MG) in vascular tissues is one of the causative factors for vascular remodelling in different subtypes of metabolic syndrome, including hypertension and insulin resistance. Fructose-induced up-regulation of aldolase B (AldoB) contributes to increased vascular MG production but the underlying mechanisms are unclear. Serum levels of MG and fructose were determined in diabetic patients with hypertension. MG level had significant positive correlations with blood pressure and fructose level respectively. C57BL/6 mice were fed with control or fructose-enriched diet for 3 months and ultrasonographic and histologic analyses were performed to evaluate arterial structural changes. Fructose-fed mice exhibited hypertension and high levels of serum MG with normal glucose level. Fructose intake increased blood vessel wall thickness and vascular smooth muscle cell (VSMC) proliferation. Western blotting and real-time PCR analysis revealed that AldoB level was significantly increased in both the aorta of fructose-fed mice and the fructose-treated VSMCs, whereas aldolase A (AldoA) expression was not changed. The knockdown of AldoB expression prevented fructose-induced MG overproduction and VSMC proliferation. Moreover, fructose significantly increased carbohydrate-responsive element-binding protein (ChREBP), phosphorylated FoxO1/3α and Akt1 levels. Fructose induced translocation of ChREBP from the cytosol to nucleus and activated AldoB gene expression, which was inhibited by the knockdown of ChREBP. Meanwhile, fructose caused FoxO1/3α shuttling from the nucleus to cytosol and inhibited its binding to AldoB promoter region. Fructose-induced AldoB up-regulation was suppressed by Akt1 inhibitor but enhanced by FoxO1/3α siRNA. Collectively, fructose activates ChREBP and inactivates FoxO1/3α pathways to up-regulate AldoB expression and MG production, leading to vascular remodelling.
© 2017 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  FoxO1/3α; aldolase B; carbohydrate-responsive element-binding protein (ChREBP); fructose; hypertension

Mesh:

Substances:

Year:  2016        PMID: 28007970     DOI: 10.1042/CS20160251

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

1.  ChREBP-Knockout Mice Show Sucrose Intolerance and Fructose Malabsorption.

Authors:  Takehiro Kato; Katsumi Iizuka; Ken Takao; Yukio Horikawa; Tadahiro Kitamura; Jun Takeda
Journal:  Nutrients       Date:  2018-03-12       Impact factor: 5.717

2.  Kidney and vascular function in adult patients with hereditary fructose intolerance.

Authors:  Nynke Simons; François-Guillaume Debray; Nicolaas C Schaper; Edith J M Feskens; Carla E M Hollak; Judith A P Bons; Jörgen Bierau; Alfons J H M Houben; Casper G Schalkwijk; Coen D A Stehouwer; David Cassiman; Martijn C G J Brouwers
Journal:  Mol Genet Metab Rep       Date:  2020-05-11

3.  Circular RNA circCHFR Facilitates the Proliferation and Migration of Vascular Smooth Muscle via miR-370/FOXO1/Cyclin D1 Pathway.

Authors:  Lei Yang; Fan Yang; Haikang Zhao; Maode Wang; Yuelin Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2019-04-06

4.  Multi-omics analysis reveals the pathogenesis of db/db mice diabetic kidney disease and the treatment mechanisms of multi-bioactive compounds combination from Salvia miltiorrhiza.

Authors:  Zhuo Xu; Xiang Xiang; Shulan Su; Yue Zhu; Hui Yan; Sheng Guo; Jianming Guo; Er-Xin Shang; Dawei Qian; Jin-Ao Duan
Journal:  Front Pharmacol       Date:  2022-09-29       Impact factor: 5.988

5.  Bioinformatics analysis of microRNA profiles and identification of microRNA-mRNA network and biological markers in intracranial aneurysm.

Authors:  Ming Zhao; Longbiao Xu; Hui Qian
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.